Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04829136 · ClinicalTrials.gov registry record · NA

Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies

A NA study of Hematopoietic and Lymphatic System Neoplasm, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04829136: Recruiting NA study of Hematopoietic and Lymphatic System Neoplasm, sponsored by Fred Hutchinson Cancer Center.

NCT04829136 is a NA study of Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 30 participants, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04829136, a NA study of Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical trial examines sustained oral fiber supplementation for patients undergoing donor stem cell transplantation for hematological malignancies. Patients undergoing donor stem cell transplantation often develop oral and gastrointestinal damage from chemotherapy, radiotherapy, or graft-versus-host disease. Oral fiber nutrition support may improve overall nutrition, support a normal gut microbiome (bacteria that live in the gut) and/or improve gut function in patients undergoing stem cell transplants.

Primary Outcome

The proportion of eligible patients who consent to enroll in the study will be computed based on the number approached and estimated with 95% confidence intervals.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Survey Administration
  • DIETARY_SUPPLEMENT Kate Farms 1.0
  • DIETARY_SUPPLEMENT Standard of Care Nutritional Support
  • DIETARY_SUPPLEMENT Dietary Supplement

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-06-22
Est. Completion 2027-12-31
Phase NA
Fred Hutchinson Cancer Center

483 total trials

What NCT04829136 shows while recruiting

NCT04829136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04829136 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT04829136 about?

NCT04829136 is a clinical study titled "Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies". This clinical trial examines sustained oral fiber supplementation for patients undergoing donor stem cell transplantation for hematological malignancies. Patients undergoing donor stem cell transplantation often develop oral and gastrointestinal damage from chemotherapy, radiotherapy, or graft-versu...

What is the current status of trial NCT04829136?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-06-22. Estimated completion is 2027-12-31.

What conditions does trial NCT04829136 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm.

What interventions are being tested in trial NCT04829136?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Kate Farms 1.0 (DIETARY_SUPPLEMENT), Standard of Care Nutritional Support (DIETARY_SUPPLEMENT), Dietary Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04829136?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04829136 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic and Lymphatic System Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04829136's enrollment target sits among peer trials

30 53rd of 62 higher than 7 of 62 other Hematopoietic and Lymphatic System Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematopoietic and Lymphatic System Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04829136, the US trial registry maintained by the National Library of Medicine. NCT04829136 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.